French National Institute of Health and Medical Research-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013192
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in therapeutic areas such as neurosciences, sciences, neurology, psychiatry, cancer, genetics, cancer, infectious diseases, metabolism, cell biology and immunology. It provides services in the areas of human diseases and research findings to the medical community, and to both national and international partners. INSERM operates under the joint authority of the French Ministry of Health and French Ministry of Research. The institute also conduct translational research and development services. It owns research units and research centers. INSERM is headquartered in Paris, France.

French National Institute of Health and Medical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2011 to YTD 2017 11
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
ILiAD Biotech Raises USD0.5 Million in Venture Financing 15
ILiAD Biotech Raises USD1 Million in Venture Financing 16
ILiAD Biotech Raises USD0.6 Million in Venture Financing 17
Partnerships 18
Genisphere Enters into Agreement with Inserm 18
TxCell Enters into R&D Agreement with Inserm Transfert 19
Evotec Enters into Research Agreement with Inserm Transfert 20
Pierre Fabre Medicament Partners with Inserm Transfert 21
AstraZeneca Enters into Research Agreement with Inserm 22
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 23
Mifcare Enters into Agreement with Inserm 24
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 25
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 27
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 29
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 30
Areva Enters into Research Agreement with French National Institute of Health and Medical Research 31
Licensing Agreements 32
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 32
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 33
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 34
Brainvectis Enters into Licensing Agreement with INSERM 35
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 36
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 37
Inserm Transfert Enters into Licensing Agreement with HalioDx 38
IntegraGen Enters into Licensing Agreement with Inserm 39
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 40
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 41
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 42
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 43
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 44
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 45
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 46
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 48
ViThera Pharma Enters into Licensing Agreement with French National Institute of Health and Medical Research and National Institute of Agricultural Research 50
French National Institute of Health and Medical Research – Key Competitors 51
French National Institute of Health and Medical Research – Key Employees 52
French National Institute of Health and Medical Research – Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Affiliate 53
Recent Developments 54
Product News 54
07/19/2016: An Antibody-based Drug for Multiple Sclerosis 54
Apr 08, 2016: An effective drug for myoclonus-dystonia, a rare disease of the nervous system 55
Feb 29, 2016: Peptimimesis: New Biotech Startup Developing Next Generation Therapeutic Peptides In Immuno -Oncology, Oncology And Immune Diseases 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Key Facts 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
French National Institute of Health and Medical Research, Deals By Therapy Area, 2011 to YTD 2017 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2011 to YTD 2017 11
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
ILiAD Biotech Raises USD0.5 Million in Venture Financing 15
ILiAD Biotech Raises USD1 Million in Venture Financing 16
ILiAD Biotech Raises USD0.6 Million in Venture Financing 17
Genisphere Enters into Agreement with Inserm 18
TxCell Enters into R&D Agreement with Inserm Transfert 19
Evotec Enters into Research Agreement with Inserm Transfert 20
Pierre Fabre Medicament Partners with Inserm Transfert 21
AstraZeneca Enters into Research Agreement with Inserm 22
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 23
Mifcare Enters into Agreement with Inserm 24
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 25
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 27
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 29
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 30
Areva Enters into Research Agreement with French National Institute of Health and Medical Research 31
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 32
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 33
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 34
Brainvectis Enters into Licensing Agreement with INSERM 35
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 36
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 37
Inserm Transfert Enters into Licensing Agreement with HalioDx 38
IntegraGen Enters into Licensing Agreement with Inserm 39
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 40
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 41
La Jolla Pharma Enters Into Licensing Agreement With Inserm To Develop Hepcidin Agonists 42
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 43
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 44
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 45
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 46
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 48
ViThera Pharma Enters into Licensing Agreement with French National Institute of Health and Medical Research and National Institute of Agricultural Research 50
French National Institute of Health and Medical Research, Key Competitors 51
French National Institute of Health and Medical Research, Key Employees 52
French National Institute of Health and Medical Research, Subsidiaries 53
French National Institute of Health and Medical Research, Affiliate 53

★海外企業調査レポート[French National Institute of Health and Medical Research-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Larsen & Toubro Infotech Ltd (LTI):企業の財務・戦略的SWOT分析
    Larsen & Toubro Infotech Ltd (LTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • DiamondRock Hospitality Co:企業のM&A・事業提携・投資動向
    DiamondRock Hospitality Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DiamondRock Hospitality Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • MOIL Limited:企業の戦略・SWOT・財務情報
    MOIL Limited - Strategy, SWOT and Corporate Finance Report Summary MOIL Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Gunvor Group Ltd:企業の戦略的SWOT分析
    Gunvor Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析
    Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • TransDigm Group Incorporated:企業のM&A・事業提携・投資動向
    TransDigm Group Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TransDigm Group Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Dynasil Corporation of America (DYSL):企業の財務・戦略的SWOT分析
    Summary Dynasil Corporation of America (Dynasil) is an electronic equipment company that develops and manufactures optics and photonics products. The company’s products include beam splitters, bandpass filters, coatings, crystal materials, imaging detectors, diffraction gratings, tunable light sourc …
  • MVV Energie AG:企業の戦略・SWOT・財務情報
    MVV Energie AG - Strategy, SWOT and Corporate Finance Report Summary MVV Energie AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Power Engineering Consulting 1 Joint Stock Company (TV1):企業の財務・戦略的SWOT分析
    Summary Power Engineering Consulting Joint Stock Company 1 (PECC1), formerly Power Engineering Consulting Company 1, a subsidiary of Vietnam Electricity, is a power company that offers engineering consulting services. The company offers engineering advisory services such as construction, design, fea …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Federal Reserve System:企業の戦略的SWOT分析
    The Federal Reserve System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Geron Corp (GERN):企業の財務・戦略的SWOT分析
    Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • BJ’s Wholesale Club Inc:企業の戦略・SWOT・財務分析
    BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report Summary BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Atlantia SpA (ATL):企業の財務・戦略的SWOT分析
    Atlantia SpA (ATL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • HSBC Trinkaus & Burkhardt Private Banking:企業の戦略・SWOT・財務情報
    HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Mednax Inc (MD)-製薬・医療分野:企業M&A・提携分析
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • HNI Corp (HNI):企業の財務・戦略的SWOT分析
    HNI Corp (HNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Telefonica, S.A.:戦略・SWOT・企業財務分析
    Telefonica, S.A. - Strategy, SWOT and Corporate Finance Report Summary Telefonica, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ssr Mining Inc
    Ssr Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Ssr Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆